Amarin Pharms Drug Patent Portfolio
Amarin Pharms owns 1 orange book drug protected by 71 US patents Given below is the list of Amarin Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10278935 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | 28 Jun, 2033 | Active |
| US10278936 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | 28 Jun, 2033 | Active |
| US10278937 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | 28 Jun, 2033 | Active |
| US10383840 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease | 28 Jun, 2033 | Active |
| US10555924 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease | 28 Jun, 2033 | Active |
| US10555925 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease | 28 Jun, 2033 | Active |
| US10568861 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease | 28 Jun, 2033 | Active |
| US10576054 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease | 28 Jun, 2033 | Active |
| US10668042 | Methods of reducing the risk of cardiovascular events in a subject | 28 Jun, 2033 | Active |
| US10786478 | Methods of reducing the risk of cardiovascular events in a subject | 28 Jun, 2033 | Active |
| US10792270 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease | 28 Jun, 2033 | Active |
| US10894028 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease | 28 Jun, 2033 | Active |
| US11000499 | Methods of reducing the risk of cardiovascular events in a subject | 28 Jun, 2033 | Active |
| US11116742 | Methods of reducing the risk of cardiovascular events in a subject | 28 Jun, 2033 | Active |
| US11298333 | Methods of reducing the risk of cardiovascular events in a subject | 28 Jun, 2033 | Active |
| US11369582 | Methods of reducing the risk of cardiovascular events in a subject | 28 Jun, 2033 | Active |
| US9603826 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | 28 Jun, 2033 | Active |
| US9610272 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | 28 Jun, 2033 | Active |
| US9623001 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | 28 Jun, 2033 | Active |
| US9693984 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | 28 Jun, 2033 | Active |
| US9693985 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | 28 Jun, 2033 | Active |
| US9693986 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | 28 Jun, 2033 | Active |
| US9918954 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | 28 Jun, 2033 | Active |
| US10842768 | Compositions and methods for lowering triglycerides | 15 Jun, 2030 | Active |
| US8410086 | Compositions and methods for lowering triglycerides | 15 Jun, 2030 | Active |
| US8455472 | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy | 15 Jun, 2030 | Active |
| US8669245 | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy | 15 Jun, 2030 | Active |
| US8710041 | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy | 15 Jun, 2030 | Active |
| US10010517 | Stable pharmaceutical composition and methods of using same | 29 Apr, 2030 | Active |
| US10265287 | Methods of reducing triglycerides and LDL-C | 29 Apr, 2030 | Active |
| US10792267 | Methods of treating mixed dyslipidemia | 29 Apr, 2030 | Active |
| US10842766 | Stable pharmaceutical composition and methods of using same | 29 Apr, 2030 | Active |
| US10881632 | Stable pharmaceutical composition and methods of using same | 29 Apr, 2030 | Active |
| US11103477 | Stable pharmaceutical composition and methods of using same | 29 Apr, 2030 | Active |
| US11154526 | Methods of treating mixed dyslipidemia | 29 Apr, 2030 | Active |
| US11213504 | Stable pharmaceutical composition and methods of using same | 29 Apr, 2030 | Active |
| US11717504 | Methods of reducing the risk of cardiovascular events in a subject | 29 Apr, 2030 | Active |
| US8298554 | Stable pharmaceutical composition and methods of using same | 29 Apr, 2030 | Active |
| US8445003 | Stable pharmaceutical composition and methods of using same | 29 Apr, 2030 | Active |
| US8445013 | Stable pharmaceutical composition and methods of using same | 29 Apr, 2030 | Active |
| US8454994 | Stable pharmaceutical composition and methods of using same | 29 Apr, 2030 | Active |
| US8501225 | Stable pharmaceutical composition and methods of using same | 29 Apr, 2030 | Active |
| US8551521 | Stable pharmaceutical composition and methods of using same | 29 Apr, 2030 | Active |
| US8563608 | Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy | 29 Apr, 2030 | Active |
| US8617593 | Stable pharmaceutical composition and methods of using same | 29 Apr, 2030 | Active |
| US8617594 | Stable pharmaceutical composition and methods of using same | 29 Apr, 2030 | Active |
| US8618166 | Methods of treating mixed dyslipidemia | 29 Apr, 2030 | Active |
| US8623406 | Stable pharmaceutical composition and methods of using same | 29 Apr, 2030 | Active |
| US8642077 | Stable pharmaceutical composition and methods of using same | 29 Apr, 2030 | Active |
| US8691871 | Methods of treating mixed dyslipidemia | 29 Apr, 2030 | Active |
| US8703185 | Stable pharmaceutical composition and methods of using same | 29 Apr, 2030 | Active |
| US8709475 | Stable pharmaceutical composition and methods of using same | 29 Apr, 2030 | Active |
| US8293727 | Methods of treating hypertriglyceridemia | 09 Feb, 2030 | Active |
| US8293728 | Methods of treating hypertriglyceridemia | 09 Feb, 2030 | Active |
| US8314086 | Methods of treating hypertriglyceridemia | 09 Feb, 2030 | Active |
| US8318715 | Methods of treating hypertriglyceridemia | 09 Feb, 2030 | Active |
| US8357677 | Methods of treating hypertriglyceridemia | 09 Feb, 2030 | Active |
| US8367652 | Methods of treating hypertriglyceridemia | 09 Feb, 2030 | Active |
| US8377920 | Methods of treating hypertriglyceridemia | 09 Feb, 2030 | Active |
| US8399446 | Methods of treating hypertriglyceridemia | 09 Feb, 2030 | Active |
| US8415335 | Methods of treating hypertriglyceridemia | 09 Feb, 2030 | Active |
| US8426399 | Methods of treating hypertriglyceridemia | 09 Feb, 2030 | Active |
| US8431560 | Methods of treating hypertriglyceridemia | 09 Feb, 2030 | Active |
| US8440650 | Methods of treating hypertriglyceridemia | 09 Feb, 2030 | Active |
| US8518929 | Methods of treating hypertriglyceridemia | 09 Feb, 2030 | Active |
| US8524698 | Methods of treating hypertriglyceridemia | 09 Feb, 2030 | Active |
| US8546372 | Methods of treating hypertriglyceridemia | 09 Feb, 2030 | Active |
| US8680144 | Methods of treating mixed dyslipidemia | 09 Feb, 2030 | Active |
| US9198892 | Composition and/or method for preventing onset and/or recurrence of cardiovascular events | 25 Sep, 2027 | Active |
| US9700537 | Composition for preventing the occurrence of cardiovascular event in multiple risk patient | 31 May, 2027 | Active |
| US8188146 | Highly purified ethyl EPA and other EPA derivatives | 27 Jan, 2020 | Expired |
Latest Legal Activities on Amarin Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Amarin Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Maintenance Fee Reminder Mailed
Critical
| 15 Jul, 2024 | US8318715 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 08 Jul, 2024 | US8314086 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 03 Jul, 2024 | US10894028 |
|
Expire Patent
Critical
| 01 Jul, 2024 | US8188146 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 19 Jun, 2024 | US10881632 |
|
Maintenance Fee Reminder Mailed
Critical
| 10 Jun, 2024 | US8293728 (Litigated) |
|
Maintenance Fee Reminder Mailed
Critical
| 10 Jun, 2024 | US8293727 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 May, 2024 | US10842768 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 08 May, 2024 | US10842766 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Apr, 2024 | US8298554 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Mar, 2024 | US10792267 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Mar, 2024 | US10792270 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 14 Mar, 2024 | US10786478 |
|
Maintenance Fee Reminder Mailed
Critical
| 15 Jan, 2024 | US8188146 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 15 Nov, 2023 | US10668042 |
Amarin Pharms's Drug Patent Litigations
Amarin Pharms's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Nov 30, 2021, against patent number US8642077. The petitioner Hikma Pharmaceuticals USA Inc. et al., challenged the validity of this patent, with Amarin Pharmaceuticals Ireland Limited as the respondent. Click below to track the latest information on how companies are challenging Amarin Pharms's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8642077 | November, 2021 |
Terminated-Settled
(14 Mar, 2022)
| Amarin Pharmaceuticals Ireland Limited | Hikma Pharmaceuticals USA Inc. et al. |
Amarin Pharms Drug Patents' Oppositions Filed in EPO
Amarin Pharms drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Feb 27, 2014, by Vogelsang-Wenke, Heike. This opposition was filed on patent number EP10704464A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP17187534A | Dec, 2021 | Cooke, Richard | Revoked |
| EP17187534A | Dec, 2021 | Hoffman Eitle Patent- und Rechtsanwälte Partnerschaftsgesellschaft mbB | Revoked |
| EP17187534A | Nov, 2021 | ELKINGTON AND FIFE LLP | Revoked |
| EP17206714A | Sep, 2021 | Hoffmann Eitle | Granted and Under Opposition |
| EP17206714A | Sep, 2021 | Cooke, Richard | Granted and Under Opposition |
| EP17206714A | Sep, 2021 | ELKINGTON AND FIFE LLP | Granted and Under Opposition |
| EP17168056A | Jun, 2021 | ELKINGTON AND FIFE LLP | Revoked |
| EP13156122A | Aug, 2020 | Hoffmann Eitle | Revoked |
| EP16152447A | Aug, 2020 | Hoffmann Eitle | Revoked |
| EP16152447A | Aug, 2020 | ELKINGTON AND FIFE LLP | Revoked |
| EP13156122A | Aug, 2020 | ELKINGTON AND FIFE LLP | Revoked |
| EP10704464A | Feb, 2014 | Sandoz AG | Revoked |
| EP10704464A | Feb, 2014 | Vogelsang-Wenke, Heike | Revoked |
Amarin Pharms's Family Patents
Amarin Pharms drugs have patent protection in a total of 44 countries. It's US patent count contributes only to 35.8% of its total global patent coverage. 6 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Amarin Pharms Drug List
Given below is the complete list of Amarin Pharms's drugs and the patents protecting them.
1. Vascepa
Vascepa is protected by 71 patents, out of which 1 has expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10278935 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
28 Jun, 2033
(8 years from now)
| Active |
| US10278936 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
28 Jun, 2033
(8 years from now)
| Active |
| US10278937 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
28 Jun, 2033
(8 years from now)
| Active |
| US10383840 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
28 Jun, 2033
(8 years from now)
| Active |
| US10555924 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
28 Jun, 2033
(8 years from now)
| Active |
| US10555925 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
28 Jun, 2033
(8 years from now)
| Active |
| US10568861 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
28 Jun, 2033
(8 years from now)
| Active |
| US10576054 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
28 Jun, 2033
(8 years from now)
| Active |
| US10668042 | Methods of reducing the risk of cardiovascular events in a subject |
28 Jun, 2033
(8 years from now)
| Active |
| US10786478 | Methods of reducing the risk of cardiovascular events in a subject |
28 Jun, 2033
(8 years from now)
| Active |
| US10792270 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
28 Jun, 2033
(8 years from now)
| Active |
| US10894028 | Methods of reducing the risk of a cardiovascular event in a subject at risk for cardiovascular disease |
28 Jun, 2033
(8 years from now)
| Active |
| US11000499 | Methods of reducing the risk of cardiovascular events in a subject |
28 Jun, 2033
(8 years from now)
| Active |
| US11116742 | Methods of reducing the risk of cardiovascular events in a subject |
28 Jun, 2033
(8 years from now)
| Active |
| US11298333 | Methods of reducing the risk of cardiovascular events in a subject |
28 Jun, 2033
(8 years from now)
| Active |
| US11369582 | Methods of reducing the risk of cardiovascular events in a subject |
28 Jun, 2033
(8 years from now)
| Active |
| US9603826 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
28 Jun, 2033
(8 years from now)
| Active |
| US9610272 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
28 Jun, 2033
(8 years from now)
| Active |
| US9623001 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
28 Jun, 2033
(8 years from now)
| Active |
| US9693984 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
28 Jun, 2033
(8 years from now)
| Active |
| US9693985 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
28 Jun, 2033
(8 years from now)
| Active |
| US9693986 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
28 Jun, 2033
(8 years from now)
| Active |
| US9918954 | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
28 Jun, 2033
(8 years from now)
| Active |
| US10842768 | Compositions and methods for lowering triglycerides |
15 Jun, 2030
(5 years from now)
| Active |
| US8410086 | Compositions and methods for lowering triglycerides |
15 Jun, 2030
(5 years from now)
| Active |
| US8455472 | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
15 Jun, 2030
(5 years from now)
| Active |
| US8669245 | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
15 Jun, 2030
(5 years from now)
| Active |
| US8710041 | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy |
15 Jun, 2030
(5 years from now)
| Active |
| US10010517 | Stable pharmaceutical composition and methods of using same |
29 Apr, 2030
(5 years from now)
| Active |
| US10265287 | Methods of reducing triglycerides and LDL-C |
29 Apr, 2030
(5 years from now)
| Active |
| US10792267 | Methods of treating mixed dyslipidemia |
29 Apr, 2030
(5 years from now)
| Active |
| US10842766 | Stable pharmaceutical composition and methods of using same |
29 Apr, 2030
(5 years from now)
| Active |
| US10881632 | Stable pharmaceutical composition and methods of using same |
29 Apr, 2030
(5 years from now)
| Active |
| US11103477 | Stable pharmaceutical composition and methods of using same |
29 Apr, 2030
(5 years from now)
| Active |
| US11154526 | Methods of treating mixed dyslipidemia |
29 Apr, 2030
(5 years from now)
| Active |
| US11213504 | Stable pharmaceutical composition and methods of using same |
29 Apr, 2030
(5 years from now)
| Active |
| US11717504 | Methods of reducing the risk of cardiovascular events in a subject |
29 Apr, 2030
(5 years from now)
| Active |
| US8298554 | Stable pharmaceutical composition and methods of using same |
29 Apr, 2030
(5 years from now)
| Active |
| US8445003 | Stable pharmaceutical composition and methods of using same |
29 Apr, 2030
(5 years from now)
| Active |
| US8445013 | Stable pharmaceutical composition and methods of using same |
29 Apr, 2030
(5 years from now)
| Active |
| US8454994 | Stable pharmaceutical composition and methods of using same |
29 Apr, 2030
(5 years from now)
| Active |
| US8501225 | Stable pharmaceutical composition and methods of using same |
29 Apr, 2030
(5 years from now)
| Active |
| US8551521 | Stable pharmaceutical composition and methods of using same |
29 Apr, 2030
(5 years from now)
| Active |
| US8563608 | Methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
29 Apr, 2030
(5 years from now)
| Active |
| US8617593 | Stable pharmaceutical composition and methods of using same |
29 Apr, 2030
(5 years from now)
| Active |
| US8617594 | Stable pharmaceutical composition and methods of using same |
29 Apr, 2030
(5 years from now)
| Active |
| US8618166 | Methods of treating mixed dyslipidemia |
29 Apr, 2030
(5 years from now)
| Active |
| US8623406 | Stable pharmaceutical composition and methods of using same |
29 Apr, 2030
(5 years from now)
| Active |
| US8642077 | Stable pharmaceutical composition and methods of using same |
29 Apr, 2030
(5 years from now)
| Active |
| US8691871 | Methods of treating mixed dyslipidemia |
29 Apr, 2030
(5 years from now)
| Active |
| US8703185 | Stable pharmaceutical composition and methods of using same |
29 Apr, 2030
(5 years from now)
| Active |
| US8709475 | Stable pharmaceutical composition and methods of using same |
29 Apr, 2030
(5 years from now)
| Active |
| US8293727 | Methods of treating hypertriglyceridemia |
09 Feb, 2030
(5 years from now)
| Active |
| US8293728 | Methods of treating hypertriglyceridemia |
09 Feb, 2030
(5 years from now)
| Active |
| US8314086 | Methods of treating hypertriglyceridemia |
09 Feb, 2030
(5 years from now)
| Active |
| US8318715 | Methods of treating hypertriglyceridemia |
09 Feb, 2030
(5 years from now)
| Active |
| US8357677 | Methods of treating hypertriglyceridemia |
09 Feb, 2030
(5 years from now)
| Active |
| US8367652 | Methods of treating hypertriglyceridemia |
09 Feb, 2030
(5 years from now)
| Active |
| US8377920 | Methods of treating hypertriglyceridemia |
09 Feb, 2030
(5 years from now)
| Active |
| US8399446 | Methods of treating hypertriglyceridemia |
09 Feb, 2030
(5 years from now)
| Active |
| US8415335 | Methods of treating hypertriglyceridemia |
09 Feb, 2030
(5 years from now)
| Active |
| US8426399 | Methods of treating hypertriglyceridemia |
09 Feb, 2030
(5 years from now)
| Active |
| US8431560 | Methods of treating hypertriglyceridemia |
09 Feb, 2030
(5 years from now)
| Active |
| US8440650 | Methods of treating hypertriglyceridemia |
09 Feb, 2030
(5 years from now)
| Active |
| US8518929 | Methods of treating hypertriglyceridemia |
09 Feb, 2030
(5 years from now)
| Active |
| US8524698 | Methods of treating hypertriglyceridemia |
09 Feb, 2030
(5 years from now)
| Active |
| US8546372 | Methods of treating hypertriglyceridemia |
09 Feb, 2030
(5 years from now)
| Active |
| US8680144 | Methods of treating mixed dyslipidemia |
09 Feb, 2030
(5 years from now)
| Active |
| US9198892 | Composition and/or method for preventing onset and/or recurrence of cardiovascular events |
25 Sep, 2027
(2 years from now)
| Active |
| US9700537 | Composition for preventing the occurrence of cardiovascular event in multiple risk patient |
31 May, 2027
(2 years from now)
| Active |
| US8188146 | Highly purified ethyl EPA and other EPA derivatives |
27 Jan, 2020
(4 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vascepa's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List